Overview

* Natera Q2 2025 revenue rises 32.2% yr/yr to $546.6 mln

* Company raises 2025 annual revenue outlook by $80 mln at midpoint

* Net loss widens to $100.9 mln in the qtr

Outlook

* Natera ( NTRA ) raises 2025 revenue outlook to $2.02 bln - $2.10 bln

* Company expects 2025 gross margin of 61% to 64%

* Natera ( NTRA ) anticipates positive net cash inflow in 2025

Result Drivers

* REVENUE GROWTH - Driven by increased product revenues and higher average selling prices

* TEST VOLUME - Processed 12.2% more tests, including a 50.6% increase in oncology tests

* GROSS MARGIN - Improved due to reduced costs and higher cash receipts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $546.60

Revenue mln

Q2 EPS -$0.74

Q2 Net -$100.90

Income mln

Q2 -$110.40

Income mln

from

Operatio

ns

Q2 $457 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Natera Inc ( NTRA ) is $197.50, about 30.1% above its August 6 closing price of $138.13

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)